No profile data available.
AnaptysBio, Inc. (ANAB) is a healthcare company in the additional cancer treatment drugs industry, based in San Diego, United States.
It reported revenue of $234.60 million for fiscal year 2025, up 157.0% from fiscal year 2024, and net income of -$13.23 million. In Q1 2026 (the quarter ended March 31, 2026) revenue was $25.56 million, down 8.0% from a year before. Its market capitalization was $1.37 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States.
AnaptysBio reported $234.60 million in revenue for fiscal year 2025, up 157.0% from $91.28 million in fiscal year 2024. In Q1 2026 revenue was $25.56 million.
$1.37 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include UroGen Pharma Ltd. (URGN), Nuvation Bio Inc. (NUVB), Inhibrx Biosciences, Inc. (INBX), Tyra Biosciences, Inc. (TYRA).